Atm reactivation reverses ataxia telangiectasia phenotypes in vivo

Sara Di Siena1, Federica Campolo2, Roberto Gimmelli3, Chiara Di Pietro3, Daniela Marazziti3, Susanna Dolci2, Andrea Lenzi4, Andre Nussenzweig5 and Manuela Pellegrini1,3,6

Abstract
Hereditary deficiencies in DNA damage signaling are invariably associated with cancer predisposition, immunodeficiency, radiation sensitivity, gonadal abnormalities, premature aging, and tissue degeneration. ATM kinase has been established as a central player in DNA double-strand break repair and its deficiency causes ataxia telangiectasia, a rare, multi-system disease with no cure. So ATM represents a highly attractive target for the development of novel types of gene therapy or transplantation strategies. Atm tamoxifen-inducible mouse models were generated to explore whether Atm reconstitution is able to restore Atm function in an Atm-deficient background. Body weight, immunodeficiency, spermatogenesis, and radioresistance were recovered in transgenic mice within 1 month from Atm induction. Notably, life span was doubled after Atm restoration, mice were protected from thymoma and no cerebellar defects were observed. Atm signaling was functional after DNA damage in vivo and in vitro. In summary, we propose a new Atm mouse model to investigate novel therapeutic strategies for ATM activation in ataxia telangiectasia disease.

Introduction
Mutations in the ataxia telangiectasia mutated (ATM) gene cause ataxia telangiectasia (A-T) syndrome, a rare disease that exhibits cancer predisposition, neurodegeneration, immunodeficiency, and premature aging of the skin and hair1–3. Many patients also exhibit somatic growth retardation and growth factor deficiency4,5. The disease is progressive, and death, caused predominantly by lung failure and cancer, generally occurs by the second or third decade of life6. At present, only symptomatic therapies are available and no cure for A-T syndrome exists.

The majority of A-T patients have mutations in ATM gene that result in complete loss of the protein7. ATM protein belongs to phosphatidylinositol 3-kinases family, including A-T and Rad3 related (ATR) and DNA-dependent protein kinase (DNA-PK) that share homologies within the catalytic domain. ATM is a key player in cell cycle checkpoint control and DNA repair after DNA double-strand breaks (DSBs) caused by endogenous sources, ionizing radiation (IR) or oxidative damage8. In response to DNA damage, >700 protein targets recognized by ATM and ATR have been identified9. Its deficiency impairs the signaling cascade indispensable for maintaining the genomic stability. Potential therapeutic approaches for the disease have been proposed, including treatments with myo-inositol, the use of antioxidants, or growth hormones supplementation10. Recently, a randomized trial showed that a short-term oral administration of the glucocorticoid, betamethasone, reduced ataxia symptoms in young A-T patients11. One promising therapeutic approach is bone marrow transplantation (BMT)12–14. BMT is already used as curative treatment for some genomic instability syndromes15,16, however, no transplantation protocols exist for A-T patients and transplantation therapy has been poorly applied17–19.
Another interesting preclinical approach is the mutation-targeted therapy that ameliorates the ATM gene function through the aminoglycoside-induced readthrough of premature termination codons and the use of antisense morpholino oligonucleotides.

The possibility of reinserting ATM protein or correcting point mutations as soon as the disease is diagnosed can be predicted to be of great benefit for A-T patients; however, whether and to what extent A-T phenotypes can be rescued, once ATM functions are restored, need to be tested in preclinical experiments. Atm null mice recapitulate most of the characteristics of A-T patients including extreme radiosensitivity, immune system deficiency, germ cell defects, and cancer predisposition. They also show several cerebellar defects despite they do not exhibit neurodegeneration. In this context, we generated a tamoxifen-inducible Atm mouse model and we asked whether wild-type Atm restoration is able to rescue the immunological, neurological and reproductive defects, improve weight gain, induce radioresistance, prevent and/or reduce tumor progression and whether these events depend on the timing of Atm reactivation. The rescue of Atm null phenotypes is shown at different timing after Atm induction and we unveil the cellular and molecular mechanisms controlling these events.

**Results**

**Generation of transgenic mice expressing the tamoxifen-inducible Atm kinase**

To spatially and temporally control Atm reactivation in vivo, we generated a mouse model carrying an activatable version of wild-type Atm, by using a bacterial artificial chromosome (BAC) recombineering strategy (Fig. 1). A sequence encoding a modified ligand-binding domain of the mouse estrogen receptor, named ERT2-LBD, which binds tamoxifen, but not endogenous estrogen, was fused in-frame to the coding sequences of wild-type Atm, by using a bacterial artifical chromosome (BAC) recombineering strategy before and bred to mice (Fig. S1a, b). Administration of 1 μM 4-OHT for 24 h elicited Atm nuclear translocation and activation following DSBs (Fig. 1d and Fig. S1b). After 4-OHT treatment, Atm signaling was restored in Atm TgERT2-LBD Atm−/− EFs damaged with bleomycin, a single- and double-strand DNA damage inducer and this response was partially counteracted by KU55933, a selective Atm inhibitor (Fig. S1c). More consistently, transgenic MEFs, treated overnight with 1 μM 4-OHT before γ-irradiation, activated an Atm-dependent signaling cascade similarly to Atm+/− MEFs (Fig. S1d). Atm and DNA-PK inhibitors were used to confirm the selectivity of Atm-dependent signaling.

Altogether, these results show that we generated a transgenic mouse model in which Atm is inactive and acquire responsiveness to DNA damage after 4-OHT treatment in vitro.

**Atm reactivation improves body growth and T-cell development**

Atm reactivation was achieved in vivo by intraperitoneal injection of tamoxifen to 45 days old Atm TgERT2-LBD Atm−/− mice (Fig. 2). Atm−/− and Atm+/− mice were also treated with tamoxifen and no toxicity of the drug was observed.

Mice were sacrificed 26 days after the injections (Fig. 2a). Tamoxifen administration rescued the body size of Atm TgERT2-LBD Atm−/− mice compared with Atm−/− and untreated transgenic mice (Fig. 2b).

We then investigated thymocyte maturation in Atm TgERT2-LBD Atm−/− mice treated or not with tamoxifen (Figs. 2c, d). In the developing thymus, Atm functions in T-cell receptor (TCR)-α gene rearrangement by facilitating the resolution of DSBs, which in turn promotes TCR-β surface marker expression and CD4 and CD8 single-positive (SP) thymocyte selection. The physiological role of Atm reactivation was at first examined by flow cytometry on freshly isolated thymocytes from Atm+/+, Atm−/− and Atm TgERT2-LBD Atm−/− mice (Figs. 2c, d).

Analysis of T-cell development revealed that the percentage of CD4-positive cells was partially recovered after tamoxifen in transgenic mice compared with knockout mice, but not in transgenic mice that were not treated with tamoxifen (Fig. 2c). Moreover, the percentage of the high and medium TCR-β-expressing T cells was increased after tamoxifen administration compared with Atm−/− and untreated transgenic mice (Fig. 2d).

Altogether, these results indicate that Atm reactivation is able to recover body growth and T-cell development.

**Atm reactivation restores male germ cell maturation and fertility**

Atm−/− males and females are infertile because of chromosomal fragmentation and impairment of...
**Diagram a:**

- pSV40
- CRE
- ERT2-LBD
- polyA
- pCRE-ERT2

**Diagram b:**

- PCR amplification
- Targeting fragment

- 5' UTR Atm
- ERT2-LBD
- 3xGly
- Atm

**Diagram c:**

- 5' UTR gene
- 5' ERT2-LBD
- 3' ERT2-LBD
- 3xGly
- Atm gene

**Diagram d:**

- Atm
- TgERT2-LBD

(See legend on next page.)
meiosis, the cellular process that controls gamete differentiation. The meiotic process starts during embryogenesis in females and establishes the oocyte pool, whereas it occurs postnatally in males and it is a continuous process that lasts lifelong. Atm null (Atm−/−) female were sterile and showed small ovaries without mature oocytes also after tamoxifen treatment resembling Atm−/− ovaries (Fig. 3a). This result confirm that the Atm transgene cannot be activated by endogenous estrogens and more widely that female meiosis cannot be rescued postnatally. Conversely, Atm TgERT2-LBD Atm−/− males showed a consistent testis size increase compared with Atm−/− males due to the presence of mature germ cells after Atm induction with tamoxifen (Fig. 3b). As expected, germ cell degeneration and complete absence of spermatids was found in testes from untreated Atm TgERT2-LBD Atm−/− mice, excluding the possibility that transgenic males variably produced mature germ cells (Fig. 3b).

Sperm collection from caudae 26 days after tamoxifen injection revealed the presence of spermatooza with normal shape and motility (Fig. 3c), although the cell number was reduced (n = 0.143 ± 0.043 x 10^6 / ml) in reactivated Atm TgERT2-LBD Atm−/− vs 0.65 ± 0.05 x 10^6 / ml in Atm+/−.

To test whether inducible Atm was acting on meiotic spermatocytes arrested in prophase, tamoxifen-induced Atm TgERT2-LBD Atm−/− males, which either underwent or not monoo-orchietomy, were sacrificed 17 days after injections (Fig. 3d). This is the shortest time needed for spermatids differentiation from meiotic cells. The analysis of testis after orchietomy (ORCH) showed a knockout phenotype (data not shown), whereas testis size was increased (Figs. 3b, d) and round and elongated spermatids were found (Fig. 3e, upper panels), 17 days after tamoxifen injections in seminiferous tubules of the contralateral testis, indicating that reactivated Atm was likely acting on meiotic prophase cells. Atm activation was confirmed by H2AX phosphorylation (γ-H2AX), a target of Atm in the sex body region of pachyten spermatoocytes (Fig. 3e, lower panels). Untreated transgenic mice showed few γ-H2AX-positive cells similarly to Atm−/− mice. Notably, transgenic males were able to fertilize females and to give pups within 2 months of continuous breeding after tamoxifen treatment (Fig. S2). The fertility rescue was restricted to this window most likely due to completion of the spermatogenetic wave. Collectively, our results show that physiological DNA rearrangements that resolve DSBs during meiotic recombination are rescued in the Atm-inducible male mouse model and they likely occur during the early stages of meiotic germ cell differentiation.

Atm restoration induces physiological responses to IR and Atm signaling cascade

Atm−/− mice have an increased sensitivity to IR. Upon radiation exposure, the death of Atm−/− mice results from acute radiation toxicity to the gastrointestinal tract. Atm TgERT2-LBD Atm−/− mice with or without tamoxifen administration were subjected to 8 Gy of whole-body γ-irradiation to evaluate the radiation sensitivity. Intestinal tissues were collected 4 days after irradiation exposure. Recovery from irradiation in the small intestines was similar in Atm+/− and Atm TgERT2-LBD Atm−/− after tamoxifen treatment, whereas Atm+/− and Atm TgERT2-LBD Atm−/− mice displayed characteristic toxicity outlined by severe epithelial crypt degeneration and loss of villi (Fig. 4a). These data indicate that Atm-inducible mouse model is able to promote DNA repair and tissue recovery after exposure to IR.

To study if cells were still able to respond in vitro to DNA damage after Atm recovery in vivo, thymocytes isolated from tamoxifen-treated Atm TgERT2-LBD Atm−/− mice were damaged with NCS. As shown in Fig. 4b, Atm signaling cascade was activated similarly to Atm+/− thymocytes in response to DNA damage. These results confirm that tamoxifen treatment drives Atm unfolding allowing Atm nuclear re-localization in an activatable state prone to respond to DNA damage.

Atm reactivation prevents/delays thymic lymphoma in Atm−/− mice

To understand whether Atm reactivation rescues Atm-null phenotypes in the long-term, Atm TgERT2-LBD Atm−/−...
Fig. 2 (See legend on next page.)
mice were monitored for several months after tamoxifen injections. *Atm*−/− mutant mice acquire fatal thymic malignancies as early as 2 months of age and, by 5 months of age, *Atm*−/− mutant mice die for thymic lymphomas with some variability depending on the housing conditions. In our animal facility, *Atm*−/− mice die within 5 months of age (Fig. 5a). Similarly, to *Atm*−/− mice, *Atm* TgERT2-LBD *Atm*−/− mice without tamoxifen injection succumbed for thymic lymphomas at similar age (Fig. 5a). Notably, Atm-inducible transgenic mice survived at least 9 months, a time at which we decided to sacrifice them for further analyses.

Atm-induced *Atm* TgERT2-LBD *Atm*−/− mice were analyzed at 9 months of age for development of mature T cells, evaluating CD4 and CD8 markers, TCR-β expression and thymoma formation (Figs. 5b–d and Fig. S3). As reported in Figs. 5b, c, around 50% of the mice showed T-cell maturation over the time and did not develop thymoma by this age. The other 50% presented tumoral expression pattern of CD4 and CD8 markers and showed thymoma (Figs. 5b, d and Fig. S3a), although reduced in size. Peripheral blood analyses revealed that double-positive CD3/CD4 cells were increased in induced *Atm* TgERT2-LBD *Atm*−/− mice compared with *Atm*−/− (Fig. S3b), suggesting that mature T-cell pool is maintained for a long period after tamoxifen treatment.

**Atm restoration rescues Purkinje cell defects**

*Atm*−/− mice do not show signs of neurodegeneration during their life span, however, several studies reported that cerebellum of A-T mouse models surviving longer than 6 months had reduced cerebellum size index, alteration of synaptic vesicle formation and release, ectopic and abnormally differentiated Purkinje cells. These defects are frequently observed in A-T patients. Inducible Atm transgenic mice similarly to *Atm*−/− mice did not show evident cerebellar phenotypes within 5 months of age (data not shown). To investigate whether reactivation of Atm was sufficient to prevent cerebellum abnormalities in older transgenic mice, we analyzed 9 months old *Atm* TgERT2-LBD *Atm*−/− mice that were treated with tamoxifen at day 45. Histological examination (Fig. 5e, left panels) and immunofluorescence analyses (Fig. 5e, right panels) did not reveal major differences in the cerebella and in Purkinje cell morphology and number between *Atm*+/− and *Atm* TgERT2-LBD *Atm*−/−, *Atm* TgERT2-LBD *Atm*−/−, and *Atm*−/− mice. The dotted line shows TCR-β expression (low, medium, and high) in freshly isolated thymocytes. Histogram shows the percentage of medium and high TCR-β-expressing cells. Data were obtained from independent experiments performed on at least n = 4 thymocyte preparations for each genotype in independent experiments.

**Discussion**

A-T is a highly pleiotropic autosomal recessive human disorder that is caused by mutations in the *ATM* gene, located on the long arm of chromosome 11 (q22–23). A-T patients exhibit thymic hypoplasia, resulting in immunodeficiency and hematologic malignancy, neurodegeneration, sterility, and radiosensitivity. Here, we report that transgenic mice carrying a regulatable *Atm* gene fused to the modified estrogen receptor ligand-binding domain (ERT2-LBD), rapidly and reversibly activate the kinase following administration of tamoxifen, the ERT2 ligand. Several proteins have been successfully regulated by ERT2/tamoxifen system (see http://www.picard.ch/downloads for protein list), and useful conditional mouse models have been recently generated. However, this is the first mouse model in which ERT2 has been fused to Atm protein, allowing to directly and temporally modulate its activation. Notably, a single series of injections, expected to activate Atm just in a limited
Fig. 3 (See legend on next page.)
period of time, was sufficient to induce thymocyte and sperm maturation, to increase body weight, to rescue germ cell, and cerebellum differentiation and more widely to maintain genomic stability and prevent/delay tumorigenesis. Meiotic germ cell arrest in \( \text{Atm}^{−/−} \) mice has been extensively studied\(^{37} \). Interestingly, we found that Atm reactivation in the meiotic phase was sufficient to restore male fertility, providing novel biological insights with potential implications in the reproductive medicine. \( \text{Atm} \) transgene might also regulate pre-meiotic germ cell survival, since pups were born within 2 months from the first tamoxifen injection, during continuous breeding. The limited temporal rescue of spermatogenesis and fertility of \( \text{TgERT2-LBD \ Atm}^{−/−} \) mice can be explained by the relatively short half-life of tamoxifen in vivo\(^{38,39} \).

Interestingly, we observed a long-term restoration of thymocyte development. For example, the percentage of CD4 and CD8 SP cells reached wild-type levels 26 days after tamoxifen injection and these levels were maintained for several months. A possible scenario is that mature thymocytes produced following Atm reactivation exit from thymus, proliferate and then they return to the organ establishing a positive feedback loop. Studies on T-cell turnover indicate that most peripheral T cells can remain in interphase for months in rodents and years in humans\(^{40,41} \). Indeed mature CD4 and CD8 cells in the extrathymic environment are kept alive by TCR contact with self-peptide/major histocompatibility complex (pMHC) ligands and exposure to interleukin-7\(^{42,43} \) before reentering into thymus where they are stored for long-term period\(^{44} \).

In previous studies of wild-type Atm BMT mouse models, the stem cells pool was described to account for thymocyte maturation and thymoma prevention\(^{12–14} \). Our data indicate that Atm restoration in inducible mice not older than 2 months was able to prevent/delay thymoma formation. We hypothesize that the long-term phenotypic rescue and tumor retardation in Atm reactivated mice is due to protection from TCR-associated translocations, which promotes thymomas. Furthermore, our data support previous hypothesis\(^{12} \) that a cell-intrinsic defect exists in T-cell progenitors as opposed to compromised microenvironment responsible for the inefficient T-cell maturation. Finally, we elucidated that malignancy protection is possible also in the case of Atm expression chimerism because in our model Atm-restored cells coexist with Atm-null cells once tamoxifen is degraded.

Altogether these results suggest that Atm restoration is theoretically a viable option for A-T patients; however, further studies are necessary to dissect the timing for tumor onset prevention or regression after tamoxifen treatment.

Exposure of mice to \( \gamma \)-irradiation revealed that reactivated Atm was able to repair DNA damage from exogenous sources other than physiological DSBs occurring during crossing over or TCR rearrangements. Small intestines appear reconstituted suggesting stem cell from crypt zone were activated upon tissue damage. Since mice were irradiated 3 weeks after tamoxifen treatment tissue repair was potentially driven by DNA-label-retaining cells, long-lived quiescent cells that represent a reservoir of stem cells in the small intestine\(^{45} \).

We further investigated whether the rescue of \( \text{Atm} \) knockout phenotypes was due to Atm signaling reactivation in response to DNA damage. Indeed, thymocytes collected from tamoxifen-induced transgenic mice were able to signal DNA damage in vitro.

Neurodegeneration is a detrimental hallmark of A-T disease caused by microscopic atrophy of the cerebellar cortex resulting from a reduction in Purkinje, granular, and basket cells. Atm-deficient mice do not show evident cerebellar defects presumably because they die at 4–6 months before their manifestation\(^{21} \). Indeed, recently, Atm mouse models in which survival was extended to 8–10 months showed that Atm-deficient mice have cerebellar defects\(^{43,45} \). To explain the later cerebellar phenotype it has been proposed that defective Atm might permit specific neuronal cell population, such as Purkinje cells to accumulate mutations that lead to functional deficits later in life\(^{46} \). Moreover, neurons of humans and mice at high risk for degeneration show clear evidence of...
having re-initiated a cell cycle process, which is uncoupled from cell death. Neurons do not complete the cell cycle and cell death is protracted for a long period that in mice last >6–12 months. Our results show that Atm restoration in the second month of mouse life extended the survival at least for 9 months and mice did not present evident cerebellar defects. Since cell cycle events in mouse cerebellum occur primarily during the third postnatal week, we hypothesize that by activating Atm before the second month of mouse life we prevented the ectopic Purkinje cell division causing neuronal abnormalities and thus cerebellum defects. Future work will focus on studying the time-dependent function of Atm on nervous system, by delaying Atm reactivation.

In summary, these results indicate that we were able to generate an Atm mouse model with the unique feature, compared with the other existent Atm mouse model, which Atm can be reactivated at any time during the mouse life span, permitting the temporal dissection of Atm functions in different cellular processes. Furthermore, this model is useful for understanding how long Atm functions can last in different cell types after the physiological turnover of the protein. In this context, our data showing that survival of Atm induced mice are consistently prolonged provide support for therapeutic interventions restoring ATM function in ATM-deficient cells and will permit future studies into the role of ATM in oxidative stress, cancer, and aging.

**Materials and methods**

**Generation of Atm<sup>TgERT2-LBD</sup> mice**

The pCRE-ERT2<sup>21,52</sup> was used to amplify the modified mouse ERT2-LBD, which responds to 4-OHT. The ERT2-LBD complementary DNA was amplified with expand long template taq (Roche, Monza, Italy), from the pCre-ERT2 plasmid<sup>52</sup>, using two 100-bp oligos surrounding Atm ATG site. Three glycine residues were introduced between the 3′ end of ERT2-LBD and the first amino acid of Atm to ensure the correct protein folding. The ERT2-LBD fragment was inserted into Atm BAC RP24 122F10<sup>26</sup> by homologous recombination to obtain Atm<sup>TgERT2-LBD</sup>. The final targeting vectors were purified and diluted (10 μg/μl) for pronuclear injection into C57Bl/6 oocytes. The presence of the transgene was determined by screening tail DNA using BAC-specific PCR primer pairs, which amplify products in LBD sequence, 5′ end of Atm (LBD Screen For 5′-CAGCATGAAAGTCAAGAGGCT-3′ and AT Screen Rev 5′-AAAACAGCATCCTACATTCCAG-3′). Several transgenic founder lines were obtained and crossed to Atm<sup>+/−</sup> mice in order to restore Atm expression in the Atm-null background. In the murine, Atm BAC was previously inserted an EcoRI site between 35 and 36 exons.
Fig. 5 (See legend on next page.)
for a PCR-based method\textsuperscript{28} to distinguish between Atm\textsuperscript{tgERT2-LBD Atm\textsuperscript{−/−}} and Atm\textsuperscript{tgERT2-LBD Atm\textsuperscript{+/−}} genotypes.

Health status of the treated mice was monitored twice a week. Mice were housed at the animal facility of Tor Vergata University, under standard conditions with free access to food diet and water. All animal studies were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals and protocols were approved by the Tor Vergata Animal Care, Ethics Committee and the Italian Ministry of Health (prot n 1104/2016-PR, art. 31 of D.lgs 24/2014).

Tamoxifen and 4-OHT treatments

To induce Atm reactivation in vivo, 45 days old mice were injected with tamoxifen (Sigma, Milan, Italy) dissolved in corn oil (Sigma). Doses were chosen according to previous articles\textsuperscript{36,53} with some adjustments: Atm\textsuperscript{tgERT2-LBD Atm\textsuperscript{−/−}} mice were treated with tamoxifen for 5 days (first day: 3.5 mg/20 g of body weight; following 4 days: 1 mg/20 g of body weight) by intraperitoneal injection.

Transgenic mice were sacrificed 17 or 26 days or 9 months after the tamoxifen injections. Atm\textsuperscript{−/−} and Atm\textsuperscript{+/+} mice were also treated with tamoxifen as control mice with no evident effects of the drug. To induce Atm in vitro, cells were treated with 4-OHT (Sigma) dissolved in ethanol at different doses (from 10 nM to 2 μM) for 24 h.

Cell isolation and western blot analysis

MEFs were derived from E13.5 Atm\textsuperscript{tgERT2-LBD Atm\textsuperscript{+/−}} and Atm\textsuperscript{tgERT2-LBD Atm\textsuperscript{−/−}} embryos by mincing embryonic carcase with sterile scalpels followed by digestion with 0.05% trypsin for 5 min, whereas to obtain mouse EFS the dorsal portion of the ear was minced and digested at 37 °C for 45 min in collagenase D/dispase (4 mg/ml in Dulbecco’s modified Eagle’s medium (DMEM), Roche). Cell suspensions were dissolved in DMEM containing 10% fetal bovine serum filtered and cultured for 48 h before use. MEFs and EFS were treated with 4-OHT (Sigma) for 24 h before stimulation with different DNA damage agents. DNA-PK inhibitor (NU7026:10 μM, Sigma) and ATM inhibitor (Kudo55933:10 μM, SelleckChem, Huston, TX, USA) were added to the medium 1 h before bleomycin (5 nM), NCS (500ng/ml, Sigma), and γ-irradiation (10 Gy) and cells were collected 1 h later, if not indicated.

T cells were isolated by gently smashing thymi in phosphate-buffered saline and then used for flow cytometry analyses or stimulated with NCS for 20 min or 1 h for protein analyses. Protein extraction was performed with lysis buffer (50 mM Tris-HCl pH7.5, 200 mM NaCl, 0.2% NP40, 50 mM β-glicerophosphate, 1% Tween 20, 0.5 M phenylmethylsulfonyl fluoride) and protease inhibitors (Sigma).

Western blots for Atm and protein targets were performed as previously described\textsuperscript{26}. Primary antibodies were used overnight at the following dilutions: anti-mouse Atm S1987p (1:500), produced by immunization with the synthetic peptide SPTFEESpQGTTISS (Becton Dickinson)\textsuperscript{36}, anti-Smc1 S957p (1:500, Rockland Immuno-chemicals, Limerick, PA, USA), anti-p53 S15p (1:500, Cell Signaling, Danvers, MA, USA), anti-p53 (1:1000, Santa Cruz, Dallas, TX, USA), anti-γH2AX (1: 1000 Upstate Biotechnology), and anti-Kap-1 S824p (1:700, Bethyl Labs, Montgomery, TX, USA), anti-tubulin (1:10,000, Sigma), anti-Actin (1:2000, Sigma), anti-Histone H3 (1:1000, Abcam, Cambridge, UK). Anti-rabbit or anti-mouse (1:10,000, Santa Cruz) were used as secondary antibodies. Bands were detected by ECL and images were recorded with the Syngene G-box system (Syngene Bioimaging, Haryana, India).

ORCH, histological procedures and Immunofluorescence

ORCH of one testis was performed under general anesthesia with averitin (250 mg/kg, Sigma) 1 week before tamoxifen treatment. The abdominal cavity was opened to remove testis epididym and part of the spermatic cord through the incision. The incision was closed with sutures. Mice received 500 μl of glucose solution (5% glucose in physiologic solution), soon after the surgery. Testes, ovaries, and small intestines were directly embedded in optical cutting temperature
compound (BioOptica, Milan, Italy) and snap-frozen or previously fixed in Bouin solution (Sigma, Missouri, USA) and then included in paraffin. Sections 7 μm thick were stained with hematoxylin and eosin (H&E; Sigma, Missouri, USA) or processed for immunofluorescence with standard protocols. Images were acquired with an inverted microscope (Axiovert 200 M; Carl Zeiss, Inc., Thornwood, NY, USA). EFs cells or 5 μm thick testis sections were fixed in paraformaldehyde 4% (Società Italiana chimici, Rome, Italy) for 10 min at room temperature before immunofluorescence staining, using standard protocols. After permeabilization and blocking with 1% bovine serum albumin (BSA), samples were incubated with mouse anti-γ-H2AX (1:100 Upstate Biotechnology) and rabbit anti-E Rβ (1:100, clone H-150, Santa Cruz) diluted in 0.5% BSA overnight at 4 °C. Secondary antibodies anti-mouse Alexa Fluor 488 or anti-mouse Alexa Fluor 568 or anti-rabbit Alexa Fluor 488 were diluted 1:400. Images were acquired by Nikon Eclipse Ti-S microscope (Nikon Instruments, Nikon Instruments S.p.A, Firenze, Italy).

Brain from 9-month-old mice were dissected and immediately fixed in paraformaldehyde 4% before paraffin embedding. Sections were processed for H&E staining with standard protocols or immunofluorescence labeling according to standard protocols with antigen retrieval. Calbindin 1 (Calb1/CalbD-28K; 1:200, clone CB-955; Sigma) was used as primary antibody and Alexa Fluor 555 as secondary antibody for Purkinje cell staining. Fluorescence micrographs were acquired with a TCS sp5 Leica laser scanning confocal microscope (Leica Microsystems, Milan, Italy), using the manufacturer’s imaging software. Experiments were performed in at least three animals for genotype. Sections of similar size in similar regions were chosen and analyzed in at least three non-adjacent sections per genotype.

Flow cytometry

Single-cell suspensions of thymocytes were stained for 20 min with anti-CD4-PE, anti-CD8-FITC, or anti-TCR-β-APC antibodies (1:50; Miltenyi Biotec, Bologna, Italy) at 4 °C. Dead cells were stained with SYTOX® Blue (Thermo Fisher Scientific-Life Technologies, Waltham, MA, USA). Analysis was performed with CyAn cytofluorimeter (Dako, Milan, Italy) and analyzed using FlowJo software (version 7.2.4). Blood was collected from mouse eyes 1 week before the sacrifice and cells stained with anti-CD45-eFluor450 antibody (1:100; eBioscience, San Diego, CA, USA) to exclude red cells and with anti-CD3-APC, anti-CD4-PE, and anti-CD8-FITC antibodies (1:50; Miltenyi Biotec) to detect mature T cells.

γ-Irradiation

For radiosensitivity experiments, mice were exposed to whole-body irradiation (8 Gy) using Gilardoni CHF 320 G X-ray generator (Gilardoni SpA, Lecco, Italy) operated at 250 kVp, 15 mA, with HVL = 1.6 mm Cu (additional filtration of 2.0 mm Al and 0.5 mm Cu). Mice were euthanized 4 days after irradiation.

Statistical analyses

All data are expressed as mean ± SEM. Samples were analyzed with one-way analysis of variance with Tukey correction or with Student's t-test, two tailed, and 1 degree of freedom. Differences were considered significant if *P < 0.05. Kaplan–Meier survival curves was plotted by using Graph Pad Prism version 6.0 (Graph pad software). P-values were obtained by the log-rank (Mantel–Cox) test.

Acknowledgements

We thank Professor Pierre Chambon (University de Strasbourg, France) for sharing the pCRE-ERT2 plasmid after MTA agreement, Dr. Lionel Feigenbaum (Leidos Biomedical Research, Inc., Frederick, MD, USA) for helping in transgenic mouse generation, Dr. Fabrizio Padula (Sapienza University, Rome, Italy) for Flow Cytometry acquisition and analyses; Dr. Gabriele Rossi (Tor Vergata University, Rome, Italy) for technical support on genotyping and histology, Dr. Maria Teresa Mancuso (ENEA, Rome, Italy) for mouse irradiation experiments; Professor Pellegrino Rossi (Tor Vergata University, Rome, Italy) for reagent sharing. This work was supported by research grants from AIRC 2009 (MFG 8904) and PRIN 2012 (prot. 2012227FLF) to M.P.

Authors’ contributions

S.D.S. generated transgenic mice, performed in vivo experiments, and analyzed data. F.C. performed western blots and help in transgenic mice generation. R.G. helped with flow cytometry experiments and analyses and brain histology. C.D. P. and D.M. performed brain histology, immunohistochemistry, and analyzed data. S.D. performed mouse surgeries, helped with experiments, and manuscript writing. A.L. helped with manuscript writing and supervision of the study. A.N. contributed to experimental design, data analysis, and manuscript writing. M.P. conceived and supervised the study, analyzed data and wrote the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.
References
1. Gatti, R. A. et al. DNA polymorphism in the human Thy-1 gene. Hum. Immunol. 22, 145–150 (1988).
2. Savitsky, K. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 749–753 (1995).
3. Lavin, M. F. & Shiloh, Y. The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol. 15, 177–202 (1997).
4. Schubert, R, Reichenbach, J. & Zelien, S. Growth factor deficiency in patients with ataxia telangiectasia. Clin. Exp. Immunol. 140, 517–519 (2005).
5. Kieslich, M. et al. Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age. Cerebellum 9, 190–197 (2010).
6. Micol, R et al. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J. Allergy Clin. Immunol. 128, 382–389 (2011).
7. Uziel, T. et al. Genomic organization of the ATM gene. Trends Biochem. Sci. 33, 317–320 (1996).
8. Ditch, S. & Paull, T. T. The ATM protein kinase and cellular redox signaling: a role in cancer susceptibility? Curr. Opin. Genet. Dev. 14, 487–490 (2004).
9. Matsuoka, S. et al. ATM and ATR substrate analysis reveals extensive protein deficiency in patients with ataxia-telangiectasia syndrome and ALL. Proc. Natl. Acad. Sci. USA 104, 6323–6328 (2007).
10. Chen, J. et al. The impact of glutamine supplementation on the symptoms of aged telomerase-deficient mice. Mol. Neurodegen. 8, 106 (2011).
11. Bagley, J., Cortes, M. L., Breake, M. L. & Wagner, J. E. Haematopoietic cell transplantation for Fan–coni anemia: a preclinical assessment. Br. J. Haematol. 128, 25–34 (2005).
12. Savitsky, K. et al. As single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 749–753 (1995).
13. Lavin, M. F. & Shiloh, Y. The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol. 15, 177–202 (1997).
14. Pietzner, J. et al. Low-dose irradiation prior to bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice. Blood 104, 572–578 (2004).
15. Pietzner, J. et al. Bone marrow transplantation improves the outcome of Atm-deficient mice through the migration of ATM-competent cells. Hum. Mol. Genet. 22, 93–507 (2013).
16. Pietzner, J. et al. Low-dose irradiation prior to bone marrow transplantation results in ATM activation and increased lethality in Atm-deficient mice. Bone Marrow Transplant. 51, 619 (2016).
17. Albert, M. H. et al. Successful SCT for Nijmegen breakage syndrome. Bone Marrow Transplant. 45, 622–626 (2010).
18. MacMillan, M. L. & Wagner, J. E. Haematopoietic cell transplantation for Fanconi anemia — when and how? Br. J. Haematol. 149, 14–21 (2010).
19. Buckley, R. H. Bone marrow and thymus transplantation in ataxia-telangiectasia. Birth Defects Orig. Artic. Ser. 11, 421–427 (1975).
20. Ghosh, S. et al. Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia. J. Clin. Immunol. 32, 438–440 (2012).
21. Ussowicz, M., Musial, J., Duzzenko, E., Haus, O. & Kalwak, K, Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL. Bone Marrow Transplant. 48, 740–741 (2013).
22. Cavaleri, S., Pozzi, E., Gatti, R. A. & Brusco, A. Deep-intronic ATM mutation detected by genomic resequencing and corrected in vitro by antitsense morpholin oligonucleotide (AMO). Eur. J. Hum. Genet. 21, 774–778 (2013).
23. Barlow, C. et al. ATM-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159–171 (1996).
24. Elson, A. et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. USA 93, 13084–13089 (1996).
25. Xu, Y. et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphopenia. Genes Dev. 10, 2411–2422 (1996).
26. Kuljis, R. O., Xu, Y., Aguila, M. C. & Baltimore, D. Degeneration of neurons, synapses, and neuroplastic and glial activation in a murine Atm knockout model of ataxia-telangiectasia. Proc. Natl. Acad. Sci. USA 94, 12688–12693 (1997).
27. Pellegrini, M. et al. Autophosphorylation at serine 1987 is dispensable for murine Atm activation in vivo. Nature 443, 222–225 (2006).